HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

Returns on capital

HLS Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-20.5%

avg -13.9%

ROIC

-3.5%

avg -2.8%

ROA

-9.2%

avg -7.3%

Analysis

ROIC is currently the strongest return metric at -3.5% versus its period average of -2.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Craig Stuart Millian

Chief Executive Officer & DirectorUSD 1.37M58——

Brian T. Walsh

Chief Operating OfficerUSD 707.68K———

John Hanna

Chief Financial Officer & Non-Independent DirectorUSD 676.87K61——

Ryan C. Lennox

Senior VP, General Counsel, Head of Corporate Governance & Corporate SecretaryUSD 550.23K45——

Jason A. Gross

Vice President of Scientific AffairsUSD 423.54K61——

Patricia Perry

Vice-President of Human Resource—50——

David Spence

Vice President & Corporate Controller—58——

Dave Mason

Investor Relations Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-2.8%
+11.5% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at -2.8% over three years. Forward estimates point to Revenue at +11.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does HLS Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about HLS.TO's management, answered from reported figures.

Who manages HLS.TO?

HLS Therapeutics Inc. (HLS.TO) lists 8 active executives. The top listed executive is Jason A. Gross, Vice President of Scientific Affairs.